Floatz logo

FILGRASTIM

Progesterone Receptor-negative Breast Cancer

University of Washingtonprotein_peptidePhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Progesterone Receptor-negative Breast Cancer cohort.

Asset / SponsorPhaseRating
Vinorelbine
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2BB
Cyclophosphamide
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2BB
Veliparib
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2BB
Irinotecan
University of Washington
Phase 2BB

View all 32 →

Same molecule, other indications

FILGRASTIM is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
79 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →